Clinical Trial Detail

NCT ID NCT01866410
Title Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Cabozantinib + Erlotinib

Age Groups: senior adult

No variant requirements are available.